SUPERNUS PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SUPERNUS PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $100.45M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $102.14M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $104.70M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $85.47M | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | $115.93M | Feb 28, 2020 |
| FY2019 | Sep 30, 2018 | $103.00M | Feb 28, 2020 |
| FY2019 | Jun 30, 2018 | $99.54M | Feb 28, 2020 |
| FY2019 | Mar 31, 2018 | $90.43M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $88.44M | Mar 1, 2019 |
| FY2018 | Sep 30, 2017 | $80.40M | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $718.95M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $661.82M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $607.52M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $667.24M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $579.78M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $520.40M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $392.76M | Apr 13, 2022 |
| FY2020 | Dec 31, 2018 | $408.90M | Mar 8, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $88.44M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $80.40M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $75.83M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $57.58M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $62.37M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $56.81M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $51.63M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $44.19M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $43.69M | Mar 16, 2017 |
| FY2016 | Sep 30, 2015 | $39.36M | Mar 16, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.55M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $73.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.32M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $60.71M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $53.42M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $126.95M | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | $33.13M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $28.86M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $32.73M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $18.34M | Feb 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.28M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $81.67M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($5.27M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $46.12M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $86.03M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $173.70M | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | $40.82M | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | $39.73M | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | $42.60M | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | $25.43M | Feb 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.24M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $108.80M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $91.59M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $74.55M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $90.47M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $75.96M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $69.10M | Apr 13, 2022 |
| FY2020 | Dec 31, 2018 | $89.21M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $49.58M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $42.79M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $485.56M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $321.58M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $336.36M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $377.22M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $304.76M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $200.68M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $153.25M | Apr 13, 2022 |
| FY2020 | Dec 31, 2018 | $154.70M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $137.91M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $106.01M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.33M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $171.95M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $111.09M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $116.83M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $127.13M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $138.40M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $143.13M | Apr 13, 2022 |
| FY2020 | Dec 31, 2018 | $128.99M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $114.64M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $66.81M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $725.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $551.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $412.0K | Feb 25, 2025 |
| FY2020 | Dec 31, 2020 | $3.45M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $2.74M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $844.0K | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.03M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $1.60M | Mar 1, 2019 |
| FY2017 | Dec 31, 2015 | $2.10M | Mar 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.37B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.28B | Feb 25, 2025 |
| FY2022 | Dec 31, 2022 | $1.70B | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | $1.69B | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $1.50B | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $1.16B | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $977.81M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $424.46M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $309.57M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $390.93M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $332.34M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $356.16M | Feb 25, 2025 |
| FY2022 | Dec 31, 2022 | $816.30M | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | $873.30M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $759.24M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $564.85M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $524.79M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $156.98M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $117.81M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $921.52M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $886.20M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $815.85M | Feb 25, 2025 |
| FY2022 | Dec 31, 2020 | $744.86M | Mar 9, 2023 |
| FY2022 | Dec 31, 2019 | $595.43M | Mar 9, 2023 |
| FY2021 | Dec 31, 2018 | $453.02M | Apr 13, 2022 |
| FY2020 | Dec 31, 2017 | $267.48M | Mar 8, 2021 |
| FY2019 | Dec 31, 2016 | $191.76M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.88M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $117.02M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $117.02M | Mar 2, 2026 |
| FY2022 | Dec 31, 2022 | $117.02M | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | $117.52M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $77.91M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 8, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $517.88M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $556.43M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $482.56M | Feb 25, 2025 |
| FY2022 | Dec 31, 2022 | $481.25M | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | $379.92M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $326.50M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $199.55M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $86.49M | Feb 28, 2020 |
| FY2018 | Jan 1, 2018 | ($24.50M) | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | ($26.82M) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.45M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $69.33M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $75.05M | Mar 2, 2026 |
| FY2022 | Dec 31, 2022 | $93.12M | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | $203.43M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $288.64M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | $181.38M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $192.25M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $100.30M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $66.40M | Mar 1, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $23.23M | Mar 15, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | 1 | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | 2 | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | 2 | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.46M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 55.74M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 54.72M | Feb 25, 2025 |
| FY2022 | Dec 31, 2022 | 53.26M | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | 53.26M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 52.87M | Apr 13, 2022 |
| FY2020 | Dec 31, 2019 | 52.53M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 52.32M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 51.31M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 49.97M | Mar 1, 2018 |